๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients

โœ Scribed by Y. Fujiwara; Terumasa Ohune; K. Okusaki; Kenji Niitani; Hidetaka Sumiyoshi; Yuji Takemoto; Naoki Yamaoka; Michio Yamakido

Publisher
Springer
Year
1996
Tongue
English
Weight
330 KB
Volume
37
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Relative bioavailability of two oral for
Relative bioavailability of two oral formulations of navelbine in cancer patients
โœ X. J. Zhou; X. R. Zhou-Pan; R. Favre; R. Rahmani ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 401 KB ๐Ÿ‘ 2 views

A study was carried out in 14 cancer patients to assess the relative bioavailability of two oral formulations of navelbine. A single 130 mg oral dose of the drug was given according to a randomized two-way crossover design as two capsules: one contained the drug in powder (formulation A, reference);

Phase I/II study of carboplatin and oral
Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer
โœ Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 665 KB

Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-